Latest news

• Lilly pitches Cyramza at bladder cancer

  The US-based pharma group said its RANGE study of Cyramza (ramucirumab) in patients with locally advanced, unresectable or metastatic urothelial carcinoma (mUC) - the most common form of bladder cancer - could

• Lilly promises solanezumab news in Alzheimer's 'before year-end'

  Among these, diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) both saw solid sales gains that did not however meet analysts' expectations, while lung cancer therapy Cyramza (ramucirumab) fell 12% thanks to

• Lilly snags first approval for sarcoma drug Lartruvo

  Lilly still has patent protection for the blockbuster in the US until 2022, and in the meantime needs Lartruvo and other recent launches such as Cyramza (ramucirumab) and Portrazza (necitumumab) to

• Lilly planning 20 new launches by 2023

  Lechleiter noted that Lilly has launched six new products in the last two years alone - including Cyramza (ramucirumab), diabetes therapies Jardiance (empagliflozin) and Trulicity (dulaglutide) and most recently Taltz (ixekizumab) for

• Lilly's psoriasis drug Taltz cleared in Europe

  Rising sales of new products such as diabetes treatments Trulicity (dulaglutide) and Basaglar (insulin glargine) and Cyramza (ramucirumab) for stomach cancer offset declines for some of Lilly's older brands, notably